**EMIG calls for broader engagement in Value-Based Pricing talks**

Whilst welcoming the latest announcement by the Department of Health and ABPI that they will ‘open up’ talks on the value assessment within the new value-based pricing system, the Ethical Medicines Industry Group (EMIG) believes engagement with third parties should be widened to ensure the scheme’s success.

EMIG Chairman Leslie Galloway said:

*“The joint statement from the Department of Health and ABPI takes an important step forward in ensuring the patient voice is captured in the proposed value-based pricing system. We have argued for some time that patient engagement during negotiations is vital to ensuring the system truly reflects their needs and results in improved patient outcomes.*

*The proposed pricing and reimbursement scheme has the potential to stimulate patient access to medicines, drive pharmaceutical R&D and encourage investment in the UK economy. However, to fully realise these aims EMIG believes negotiations should be widened to all relevant stakeholders.*

*EMIG is calling for an all-industry and broad stakeholder consultation on the shape of proposals. Only by doing this will we enable ownership of the scheme across all stakeholders and deliver the true potential of value-based pricing. ”*

**Notes to Editors:**

For further information please contact Lisa Timothy on:

T: 0207 025 2342

E: lisa.timothy@lexcomm.co.uk

**About EMIG (**[www.emig.org.uk](http://www.emig.org.uk)**)**

The Ethical Medicines Industry Group (EMIG) is the specialty biopharmaceutical trade association that represents the interests of over 200 companies based in the UK. EMIG member companies range from start-ups, whose primary focus is research and development (R&D), to highly developed businesses delivering essential products to patients and the NHS.

They are commonly, but not exclusively, small to medium-sized enterprises (SMEs) which specialise either in the delivery of medicines to treat rare and underserved diseases, or focus their efforts on discrete disease areas, for example diabetes and neuropsychiatric disorders. It is estimated that 90 per cent of pharmaceutical companies are SMEs in the UK. EMIG member companies employ approximately 10,000 people in the UK and have a combined annual turnover of £2bn.